MedTrace Logo

Budesonide for Maintenance Treatment of Collagenous Colitis

NCT00180076 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2010-03-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether orale budesonide is effective in maintaining clinical remission in patients with collagenous colitis.

Conditions

  • Collagenous Colitis

Interventions

DRUG

Budesonide

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Stephan Miehlke, Prof. · Medical Department I, Technical University Hospital, Dresden, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2007-03-31
Completion
2008-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180076 on ClinicalTrials.gov